Oryzon Genomics S.A.
OTC: ORYZF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carlos Manuel Buesa Arjol
- Employees
- 47
- Headquarters
- Cornellà de Llobregat, Spain
- IPO year
- 2020
- Market cap
- $282.5M
- Website
- https://www.oryzon.com
Loading ORYZF…
Loading profile data…Frequently asked questions about ORYZF
What does Oryzon Genomics S.A. (ORYZF) do?
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company dedicated to advancing epigenetics-based therapies for individuals battling cancer and central nervous system (CNS) conditions. The company's clinical pipeline features two key compounds. Iadademstat (ORY-1001), a selective LSD1 inhibitor, is currently undergoing Phase II trials...
Where does ORYZF trade?
Oryzon Genomics S.A. (ORYZF) trades on the Other OTC.
What sector is ORYZF in?
Oryzon Genomics S.A. (ORYZF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Oryzon Genomics S.A.?
Carlos Manuel Buesa Arjol is the chief executive officer of Oryzon Genomics S.A. (ORYZF).
Where is Oryzon Genomics S.A. headquartered?
Oryzon Genomics S.A. is headquartered in Spain.
Does ORYZF pay a dividend?
Oryzon Genomics S.A. (ORYZF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ORYZF go public?
Oryzon Genomics S.A. (ORYZF) completed its initial public offering in 2020.